Provider Briefing: Azathioprine Supply in 2026

Azathioprine remains a cornerstone immunosuppressant across multiple specialties — from transplant medicine and rheumatology to gastroenterology, dermatology, and neurology. As a prescriber, you've likely encountered patients reporting difficulty filling their Azathioprine prescriptions. This briefing summarizes the current supply situation and provides actionable guidance for clinical practice.

Current Shortage Timeline

The Azathioprine supply situation has evolved over the past two years:

• 2022-2023: Periodic shortages of the injectable formulation (azathioprine sodium 100 mg vials) began surfacing due to manufacturing disruptions at key facilities.
• 2024: Hikma, one of the primary injectable manufacturers, placed azathioprine sodium 100 mg vials on back order with no estimated release date (last updated December 2024).
• 2025-2026: The injectable shortage persists. Oral tablet supply (50 mg generic, 75 mg and 100 mg Azasan) is not on the FDA's formal shortage list but patients continue to report intermittent availability gaps at individual pharmacy locations.

The oral formulation shortage is better characterized as distribution unevenness rather than a true supply deficit — the medication is being manufactured, but not every pharmacy has it on hand at every moment.

Prescribing Implications

The supply situation has several clinical implications worth considering:

Continuity of Therapy

For transplant patients, any gap in immunosuppression carries rejection risk. Proactively discuss refill logistics with transplant patients and consider prescribing 90-day supplies when clinically appropriate.

For autoimmune disease patients (RA, IBD, lupus, myasthenia gravis), abrupt discontinuation may trigger disease flares. Counsel patients to initiate refills at least 7-10 days before running out.

Formulation Flexibility

When a specific strength is unavailable, consider adjusting to an available formulation:

• Generic Azathioprine 50 mg tablets (scored, can be halved for 25 mg dosing)
• Azasan 75 mg tablets
• Azasan 100 mg tablets

Dosing adjustments to accommodate available strengths may improve patient access. Document the rationale in the chart.

TPMT/NUDT15 Testing

If considering switching a patient from Azathioprine to an alternative (or vice versa), ensure TPMT and NUDT15 genotyping results are on file. Approximately 10% of patients have intermediate TPMT activity and 0.3% are homozygous deficient — these patients require significant dose adjustments or should avoid thiopurines entirely.

Current Availability Picture

Here's what's available and what's constrained:

• Available: Generic Azathioprine 50 mg tablets from multiple manufacturers; Azasan 75 mg and 100 mg tablets
• Constrained: Azathioprine sodium injection 100 mg vials (Hikma — back ordered, no ETA)
• Brand availability: Imuran (brand) 50 mg tablets may be available at some pharmacies but at significantly higher cost

Oral tablets are generally obtainable with some effort — the issue is typically at the individual pharmacy level rather than a systemic manufacturing shortage.

Cost and Access Considerations

Azathioprine remains one of the most affordable immunosuppressants available:

• Generic cash price: $13-$17/month for 50 mg x 30 tablets with discount coupons (GoodRx, SingleCare)
• Without coupons: $40-$70/month for a 30-day supply
• Insurance coverage: Typically Tier 1 or Tier 2 on most commercial and Medicare Part D formularies
• Prior authorization: Generally not required for FDA-approved indications; may be required for some off-label uses depending on the payer

For patients with financial barriers, direct them to coupon platforms (GoodRx, SingleCare) or third-party assistance through NeedyMeds.org and RxAssist.org. There are no active manufacturer savings programs for generic Azathioprine. Prescription Hope offers a $70/month access program.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate the availability landscape:

• Medfinder for Providers: A real-time pharmacy stock checker that helps locate Azathioprine near your patient's location. Consider recommending it at the point of prescribing.
• ASHP Drug Shortage Database: Monitor the American Society of Health-System Pharmacists' shortage list for updates on Azathioprine injectable and other affected formulations.
• FDA Drug Shortage Database: Check the FDA's current list at accessdata.fda.gov for official shortage status and manufacturer communications.

For a patient-facing resource on finding this medication, you can share our guide: How to find Azathioprine in stock near you.

Alternative Immunosuppressants

When Azathioprine is truly unavailable or a patient cannot tolerate it, consider these alternatives based on indication:

• Organ transplant: Mycophenolate Mofetil (CellCept/Myfortic) is the most common substitute. Tacrolimus (Prograf) may also be adjusted if Azathioprine was part of a multi-drug regimen.
• Rheumatoid arthritis: Methotrexate (first-line DMARD), Leflunomide (Arava), or biologic DMARDs.
• IBD: Mercaptopurine (6-MP) is pharmacologically equivalent as the active metabolite. Methotrexate or biologics (infliximab, adalimumab) are alternatives.
• Myasthenia gravis: Mycophenolate Mofetil is increasingly used. Methotrexate is also an option per recent evidence.
• Lupus/autoimmune: Mycophenolate, Methotrexate, or Cyclophosphamide for severe cases.

For a patient-facing overview, refer to our article on Azathioprine alternatives.

Looking Ahead

The oral Azathioprine supply situation is expected to remain manageable through 2026, though individual pharmacy-level stock gaps will continue. The injectable shortage timeline remains uncertain pending manufacturer resolution.

Key actions for your practice:

1. Proactively address refill logistics with patients on Azathioprine
2. Maintain awareness of available formulation strengths
3. Ensure TPMT/NUDT15 results are documented for all patients on thiopurines
4. Direct patients to Medfinder for real-time stock information
5. Have a documented alternative therapy plan for each patient in case of extended unavailability

Final Thoughts

Azathioprine availability in 2026 requires more planning than it once did, but the medication remains accessible for most patients with some effort. As a prescriber, you can make a significant difference by anticipating supply issues, communicating proactively with patients, and having clear alternative protocols in place.

For additional clinical guidance on helping patients navigate access challenges, see our provider guide: How to help your patients find Azathioprine in stock.